In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases.Shots:The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations for our…
